Charles River Laboratories Intl. Inc vs GE Vernova Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $226.11 (market cap $11.14B), while GE Vernova Inc trades at $1,024.45 (market cap $286.46B). The key difference: GE Vernova Inc is far larger — about 25.7× Charles River Laboratories Intl. Inc's market cap, and GE Vernova Inc pays a 0.19% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GEV | |
|---|---|---|
Market Cap | $11.14B | $286.46B |
Sector | Health | Technology |
52-Week High | $233.60 | $1.17K |
52-Week Low | $145.57 | $547.96 |
Enterprise Value | $14.00B | $279.09B |
Dividend Yield | — | 0.19% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
GE Vernova (GEV) trades at $1,042.60, down 4.49% today, amid mixed technical signals but strong fundamental momentum. The stock shows bullish moving averages and oversold RSI conditions, while recent earnings beats and a 23.81% net income margin highlight robust profitability. Analyst consensus remains strongly bullish with a $1,240 price target, supported by the company's $11 billion investment in grid reliability and nuclear energy expansion.
Outlook: GEV's leadership in AI power infrastructure and nuclear technology positions it for long-term growth, though high valuation multiples (P/E 31.15) and execution risks on capital investments warrant caution. Near-term catalysts include Q2 2026 earnings on July 22, 2026, and dividend payments in July.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →GE Vernova is a global leader in the electric power industry. It provides sustainable energy solutions across gas, wind, and hydro sectors, focusing on modernizing the world's power grids.
Read more on GEV →